ANGIOGENIC CONTROL, PREFERABLY COMBINED WITH GLYCAEMIC CONTROL
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Dec 5, 2024
app pub date -
Oct 5, 2022
filing date -
Oct 5, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The invention relates to a distinct and newly emerging class of drugs: peptide modulators of mTOR that act as autophagy inhibiting compounds and target the nutrient sensing system of the mechanistic target of rapamycine (mTOR) and induce angiogenic activity. The invention provides formulations, methods, and means to prevent or treat vasculopathy, in particular diabetic vasculopathy, to achieve or maintain angiogenic control, preferably concomitant with glycaemic control.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully